Objective. Low-dose methotrexate (MTX) is often used in the treatment of rheumatoid arthritis (RA). To be effective, treatment must be long-term, and there are concerns that MTX may impair bone formation in a population already predisposed to osteoporosis. The purpose of this investigation was to determine the direct effects of MTX at clinically relevant doses on the growth and differentiation of human cells of the osteoblast (bone-forming) lineage.
The drug methotrexate (MTX) is used in high doses (100-1000 mgum 2 ) to treat malignancies w1x and in low doses (5-25 mguweek) to treat rheumatoid arthritis (RA) and other inflammatory conditions w2x. The main action of MTX is inhibition of dihydrofolate reductase, which reduces dietary folate to tetrahydrofolate, an essential cofactor in DNA and RNA synthesis, although MTX also has many other effects on cytokines and the inflammatory response w3x. High-dose MTX impairs bone formation, particularly in children w4, 5x, and there are case reports of fragility fractures in adults on longterm, low-dose MTX therapy for conditions such as RA and psoriatic arthritis w6-8x. In vivo studies have used high-dose and low-dose MTX, both in normal animals and in animal models of arthritis. Low-dose MTX (corresponding to the doses used to treat RA in humans), when given to normal rats, suppressed osteoblast function w9x. However, when given to rats with adjuvant-induced arthritis, bone mass was maintained in the MTX-treated animals compared with controls (which also had adjuvant arthritis) w10x. In vitro, MTX has been reported to inhibit the proliferation of cells of the osteoblast lineage but to have no effect on their differentiation w11, 12x. As RA predisposes patients to osteoporosis, it would be undesirable to use a drug as therapy which may adversely affect bone formation and therefore increase the risk of fragility fractures.
In the present study, the effects of MTX on parameters of growth and differentiation in cultures of human bone-derived cells (HBDC) were investigated. Cultures derived from the marrow stroma wbone marrow stromal cells (BMSC)x were used to assess the effects of the drug on the colony-forming potential and osteogenic differentiation of the primitive mesenchymal precursors wcolony-forming units, fibroblastic (CFU-F)x that are a source of bone-forming cells in the adult skeleton wreviewed in 13x. Cultures derived from explants of trabecular bone were used to assess the effects of MTX on the proliferation and further maturation of cells of the osteoblast lineage (HBDC). Experiments were conducted on cells cultured in the absence and presence of the synthetic glucocorticoid dexamethasone (Dx; 10 nM), as this has been shown to promote the differentiation and further maturation of cells of the osteoblast lineage in both culture types w14 -16x. On the basis of the findings of Bologna et al. w17x, MTX was used at 1-1000 nM. These authors assayed the concentrations of MTX in the synovial membrane and cortical and trabecular bone of 10 RA patients treated with the drug for a mean duration of 26 months. They were able to do this because the patients were undergoing surgery; five were having wrist synovectomy, two each having shoulder and knee arthroplasty and one having a hip arthroplasty. The day prior to surgery, each patient had an intramuscular injection of 10 mg MTX. They were found to have similar high mean levels of MTX in the synovial membrane (0.285 nmolug) and in both trabecular (0.292 nmolug) and cortical (0.286 nmolug) bone, while the plasma concentration was 10-fold less (0.0252 nmoluml).
Materials and methods

Cell culture
The methods used for the isolation, culture and subculture of BMSC and HBDC have been described in detail elsewhere and were followed without further modification w14, 15x. For both cell types the starting material was segments of rib from six patients undergoing thoracotomy: three were males, age range 19-83 yr, and four had a malignancy (lung or oesophageal cancer). The other two diagnoses were recurrent pneumothorax and diaphragmatic hernia. Consent was given by subjects for use of the tissue. No patients had arthritis and one woman was on hormone replacement therapy, but none were on other medication known to affect bone.
Colony formation
After 21 days, colonies were washed with phosphatebuffered saline (Ca 2+ -and Mg 2+ -free), pH 7.4, fixed for 5 min at room temperature and then allowed to air-dry. Colonies were stained with fast red and then methylene blue, and the number of colonies formed containing 050 cells and the proportion expressing alkaline phosphatase (AP) were determined as previously described w18x using an Olympus SZ-CTV microscope (315 objective).
Cell number
The number of BMSC was determined as described previously w16x, using an electronic particle counter (Coulter Electronics, Luton, UK). The number of HBDC was determined indirectly using an assay based on the binding of methylene blue stain to the fixed cell layer w11, 19x. We w16, 20x and others w21x have reported previously that cells derived from different donors exhibit marked variation in their capacity for proliferation. For this reason, and for the sake of clarity, the proliferation data are presented as a percentage of control.
Expression of the developmental markers STRO-1 and AP STRO-1 is a trypsin-resistant, cell-surface antigen expressed by a subset of human marrow stromal cells that includes essentially all assayable CFU-F w22x. We w23x and others w24x have shown that a monoclonal antibody recognizing this antigen can be used in combination with one recognizing the boneuliveukidney isozyme of AP (B4-78 w25x) to identify cells of the osteoblast lineage at different stages of maturation. The monoclonal antibody STRO-1 (IgM subclass) was obtained from Dr Paul Simmons (Peter MacCallum Cancer Institute, Melbourne, Australia) and B4-78 (IgG1 subclass) from the Developmental Studies Hybridoma Bank (University of Iowa, IA, USA). The expression of these antigens was monitored by flow cytometry (FACSStar Plus ; Becton Dickinson) as described previously and without further modification w16, 23x.
Statistics
Experiments were routinely set up with quadruplicates of each condition. Results were analysed with the paired t-test or analysis of variance (ANOVA) with Fisher's protected least significant difference (PLSD), and the level of significance was set at 95%.
Results
Colony-forming efficiency Treatment with MTX (1-1000 nM), irrespective of the presence or absence of Dx, had no consistent effect on the total number of colonies that formed or on the proportion that expressed the developmental marker AP (Fig. 1) .
Proliferation of BMSC
At concentrations 010 nM, treatment with MTX was associated with a statistically significant decrease in the number of cells harvested at the end of secondary culture. The magnitude of the observed decrease was similar in control and Dx-treated cultures (Fig. 2) .
Expression of the developmental markers STRO-1 and AP In cultures derived from three donors, treatment in primary and secondary culture wtotal of 71 " 3 days (mean " S.E.M.)x with 100 nM MTX had no consistent effect on the proportion of cells that expressed STRO-1, AP or both markers in combination (Fig. 3 and Table 1 ).
Proliferation of HBDC
Treatment with MTX (1-1000 nM) did not affect the proliferation of HBDC whether cultured in the absence or presence of 10 nM Dx (Fig. 4) .
HBDC expression of the developmental marker AP Treatment of HBDC with MTX (1-1000 nM) did not affect either basal or Dx-stimulated expression of AP (Fig. 5 ).
Discussion
Concerns have been expressed that low-dose MTX, as used in the treatment of RA, might have deleterious effects on bone formation. This prompted us to investigate the direct effects of this disease-modifying anti-rheumatic drug on human cells of the osteoblast lineage in vitro. In adults, bone cells of the osteoblast lineage are derived from primitive mesenchymal precursors (CFU-F) associated with the soft, fibrous tissue of the marrow stroma and bone surfaces. Our results show that treatment with MTX, at concentrations similar to those measured in the bones of RA patients w17x, has no consistent effect on the ability of these cells to assume an adherent phenotype and form colonies when explanted in vitro. In addition, they show that treatment with MTX has no consistent effect on their ability to give rise to cells of the osteoblast lineage (no effect on the expression of STRO-1 anduor AP) under basal conditions or when stimulated with 10 nM Dx. They do, however, indicate that the proliferative potential of these primitive precursors anduor their immediate progeny may be affected adversely by treatment with MTX at concentrations 010 nM.
In contrast to the results obtained in cultures of BMSC, no consistent effect of MTX was observed on proliferation in cultures of HBDC. These cells have been characterized extensively and, when compared with BMSC, shown to express a more mature osteoblastlike phenotype w14-15x. This suggests that the inhibitory effects of MTX on proliferation may be restricted to less mature cells of the marrow stromal hierarchy, as has been shown recently by Uehara et al. w26x using cultures derived from murine bone and marrow. Consistent with this possibility, although we found no effect of MTX on the proliferation of HBDC in secondary culture, we did observe that its inclusion in primary culture delayed the appearance of cells on the surface of and migration from the trabecular explants (data not shown). 
BMSC derived from multiple donors (n = 3) were cultured ("10 nM Dx) for a total of 71 " 3 days (mean " HBDC can be induced to undergo further osteogenic maturation by culture in the presence of a physiologically equivalent amount of glucocorticoid w14, 15x, in this case 10 nM Dx. Our results show that this potential for further maturation is not compromised by culture in the presence of MTX, at least when assessed on the basis of increased expression of AP.
In an earlier study, and in contrast to the results presented here, Scheven et al. w11x found that the proliferation of HBDC, assessed, as in this study, using an assay based on the binding of methylene blue, was inhibited by MTX at concentrations 010 nM. The reason(s) for this discrepancy in our findings is not entirely clear. One possibility is the use of cells from donors with different underlying pathology anduor from different skeletal sites (ribs vs head of femur). Another is our use of improved conditions of culture, particularly with regard to the maintenance of adequate ascorbate nutrition, which have been shown to enhance the proliferation and osteogenic differentiation of HBDC w14, 15x.
The results of in vivo investigations suggest that low-dose MTX, as used in the treatment of RA, does not adversely affect histomorphometric or biochemical (urinary deoxypyrodinoline) indices of bone resorption w27, 28x. To our knowledge, the direct effects of MTX on human cells of the osteoclast lineage have not been investigated; this reflects the difficulty in isolating cells of this type in a number and purity sufficient for further investigation, compared with cells of the osteoblast lineage. Recently, however, considerable progress has been made in this regard w29-32x, and it is to be hoped that this will lead to improved understanding of the direct effects of MTX on human osteoclasts and their immediate precursors.
In conclusion, we have shown that treatment with MTX can inhibit the proliferation of CFU-F and their immediate progeny, but that it does not appear to exert a direct inhibitory influence on the proliferation anduor differentiation of cells of the osteoblast lineage. From a clinical perspective this result is reassuring, as it provides additional evidence to support the hypothesis that long-term use of MTX in the treatment of RA is unlikely to have a major impact on bone formation. In a prospective study of 116 patients with RA this proved to be the case w28x.
